A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (NCT07124078)

🧪 Interventions in This Study

• INCA034176 (DRUG)
• Best available Treatment (BAT) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (41 Sites)

Showing the first 25 of 41 sites.

• City of Hope Medical Center — Duarte, California
• Children'S Hospital Los Angeles Specialt — Los Angeles, California
• Lucile Packard Child Hospital End — Palo Alto, California
• Childrens National Medical Center — Washington D.C., District of Columbia
• Adventhealth Pediatric Cellular Therapy and Blood and Marrow Transplant — Orlando, Florida
• Childrens Healthcare of Atlanta — Atlanta, Georgia
• Memorial Sloan Kettering Cancer Center — New York, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Duke Cancer Center — Durham, North Carolina
• Childrens Hospital of Pittsburgh — Pittsburgh, Pennsylvania
• Fred Hutchinson Cancer Research Center — Seattle, Washington
• Hôpital Universitaire Des Enfants Reine Fabiola — Brussels,
• Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc — Woluwe-Saint-Lambert,
• Charite Campus Virchow — Berlin,
• Klinikum Der Johann Wolfgang Goethe-Universitaet — Frankfurt am Main,
• Universitaetsklinikum Freiburg Kinder- Und Jugendklinik (Kjk) — Freiburg im Breisgau,
• Universitaetsklinikum Hamburg-Eppendorf — Hamburg,
• Medizinische Hochschule Hannover (Mhh) - Zentrum Fuer Kinderheilkunde Und Jugendmedizin - Klinik Fue — Hanover,
• University Hospital Regensburg — Regensburg,
• Irccs - Aou Di Bologna - Sant'Orsola Malpighi — Bologna,
• Irccs Istituto G. Gaslini, Universita Di Genova — Genova,
• Fondazione Irccs San Gerardo Dei Tintori — Monza,
• Azienda Ospedaliera Universitaria Di Padova — Padua,
• Fondazione Irccs Policlinico San Matteo Di Pavia Oncoematologia Pediatrica, Universita Di Pavia — Pavia,
• Irccs Ospedale Pediatrico Bambino Gesu — Rome,

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Graft-versus-host-disease

• A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease — Phoenix, Arizona
• A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) — Birmingham, Alabama
• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Birmingham, Alabama

Explore by condition: All Chronic Graft-versus-host-disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.